Literature DB >> 28964933

Endonasal dacryocystorhinostomy in children: Our experience.

Hetal Marfatia1, Keya Shah2, Swapna Patil1, Yogesh Parmar1.   

Abstract

INTRODUCTION: Epiphora affects approximately 20% neonates, but most resolve spontaneously. Dacryocystorhinostomy (DCR) is indicated only when conservative management fails.
OBJECTIVE: To observe clinical presentation, treatment modalities and effectiveness of endoscopic DCR in paediatric population.
METHODS: It is a prospective study of 21 children done at our tertiary care hospital from 2011 to 2016. All were initially subjected to a trial of conservative management. Those that responded and didn't require surgery were excluded.
RESULTS: The age group ranged from 40 days to 11.5 years. 19 underwent unilateral & 2 underwent bilateral endoscopic DCR. After a 6 month follow-up, 20 children were benefitted by surgery, 2 had an incomplete resolution and 1 required revision surgery. The overall success rate was 95.23% and failed cases were mainly due to post-traumatic distortion of the anatomy. No major complications were noted.
CONCLUSION: Endoscopic DCR is safe and effective in children presenting with persistent epiphora.
Copyright © 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Child; Dacryocystorhinostomy; Pediatrics; Postoperative complications; Stents

Mesh:

Year:  2017        PMID: 28964933     DOI: 10.1016/j.ijsu.2017.09.064

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  2 in total

1.  A Prospective Longitudinal Study to Evaluate the Outcomes of Success of Endoscopic DCR in Pediatric Age Group.

Authors:  Renu Poonia; Yogesh Aseri; Digvijay Singh Rawat; B K Singh
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2020-09-02

2.  Laser-assisted dacryocystorhinostomy in nasolacrimal duct obstruction: 5-year follow-up.

Authors:  Mustafa Doğan; Anar Alizada; Güliz Fatma Yavaş; Orhan Kemal Kahveci; Osman Bakan
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.